News - Page 77

    Is Citigroup Poised to Outshine in a Turbulent Market?

    Is Citigroup Poised to Outshine in a Turbulent Market?

    Citigroup Inc. demonstrates resilience amid economic uncertainty, with a 40% rise in net income to $12.7 billion in 2024. Key drivers include strategic trading, deal-making, and an 18% reduction in operating expenses in Q4. A $25 billion private credit partnership with Apollo
    25. February 2025
    Eli Lilly’s Strategic Moves: A Game-Changer Amid Market Waves

    Eli Lilly’s Strategic Moves: A Game-Changer Amid Market Waves

    Eli Lilly’s stock soared by 2.6% amid market challenges, driven by strategic decisions. The acquisition of Organovo’s FXR program positions Lilly to address ulcerative colitis and MASH. Innovations like tirzepatide medication, Zepbound, demonstrate Lilly’s competitive pricing strategy. Zepbound pricing at $349 and
    25. February 2025
    Why Viking Therapeutics is Turning Heads Despite Financial Storms

    Why Viking Therapeutics is Turning Heads Despite Financial Storms

    Viking Therapeutics’ stock soared over 10% despite rising financial challenges, closing at $32.29. The surge was driven by optimism for VK2735, a potential breakthrough weight loss drug. The company exemplifies entrepreneurial resilience amid market volatility, drawing investor interest. Target price adjustments by
    25. February 2025
    1 75 76 77 78 79 479

    Languages